Milestone Pharmaceuticals to host Commercial Launch Plan investor event

Milestone announced further details on its in-person and virtual Commercial Launch Plan investor event to take place in New York on Tuesday, February 25, 2025 from 10:30 AM to 12:30 PM. Featuring presentations by Joseph Oliveto, President and CEO, and Lorenz Muller, CCO, the event will provide an overview of Milestone’s commercial strategy for etripamil nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia. Milestone’s New Drug Application for CARDAMYST is currently under review at the U.S. Food and Drug Administration with a Prescription Drug User Fee Act target date of March 27, 2025. Milestone currently expects to launch in PSVT mid-2025.